AI-First Approach to Cancer Diagnostics Earns Ibex Medical Analytics Notable Milestones
Ibex Medical Analytics, the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced major advancements in customer growth, validation through a Quest Diagnostics study, regulatory approvals and expansion of its Board of Directors.
Commercial buildings and institutional facilities consume 17% of the public freshwater supply in the United States and are also significant sources of waste. Up to 25% of that water is ultimately wasted due to the lack of proper monitoring and management of water.
Ibex exemplifies that AI-powered cancer diagnostics and digital pathology are not the future but the present, with pathologists using their cutting edge-technology and tools in routine practice around the world. The company has seen a 157% increase in patient cases processed monthly via Ibex’s AI solution and 178% rise in new customers, reflecting its expanded global reach and commitment to collaborating closely with pathologists to enhance diagnostic accuracy, efficiency and helping improve patient outcomes.
Ibex's commitment to clinical excellence was validated through recent In Vitro Diagnostic Medical Devices Regulation (IVDR) Certifications, as well as data published in a recent study with Quest Diagnostics on the impact of AI-powered workflows. With a new addition to its Board of Directors and key collaborations driving innovation, Ibex continues to strengthen its position at the forefront of AI-driven healthcare solutions.